<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>200104</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10190902</PubmedId>
            <Abstract>Experimental leishmaniasis offers a well characterized model of T helper type 1 cell (Th1)-mediated control of infection by an intracellular organism. Susceptible BALB/c mice aberrantly develop Th2 cells in response to infection and are unable to control parasite dissemination. The early CD4(+) T cell response in these mice is oligoclonal and reflects the expansion of Vbeta4/ Valpha8-bearing T cells in response to a single epitope from the parasite Leishmania homologue of mammalian RACK1 (LACK) antigen. Interleukin 4 (IL-4) generated by these cells is believed to direct the subsequent Th2 response. We used T cells from T cell receptor-transgenic mice expressing such a Vbeta4/Valpha8 receptor to characterize altered peptide ligands with similar affinity for I-Ad. Such altered ligands failed to activate IL-4 production from transgenic LACK-specific T cells or following injection into BALB/c mice. Pretreatment of susceptible mice with altered peptide ligands substantially altered the course of subsequent infection. The ability to confer a healer phenotype on otherwise susceptible mice using altered peptides that differed by a single amino acid suggests limited diversity in the endogenous T cell repertoire recognizing this antigen.</Abstract>
            <ArticleYear>1999</ArticleYear>
            <ArticlePages>1111-20</ArticlePages>
            <ArticleTitle>Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Pingel</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Launois</LastName>
                    <ForeName>P</ForeName>
                </Author>
                <Author>
                    <LastName>Fowell</LastName>
                    <ForeName>D J</ForeName>
                </Author>
                <Author>
                    <LastName>Turck</LastName>
                    <ForeName>C W</ForeName>
                </Author>
                <Author>
                    <LastName>Southwood</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Sette</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Glaichenhaus</LastName>
                    <ForeName>N</ForeName>
                </Author>
                <Author>
                    <LastName>Louis</LastName>
                    <ForeName>J A</ForeName>
                </Author>
                <Author>
                    <LastName>Locksley</LastName>
                    <ForeName>R M</ForeName>
                </Author>
            </Authors>
            <Affiliations>Departments of Medicine, Microbiology, and Immunology, University of California San Francisco, San Francisco, California 94143, USA.</Affiliations>
            <ArticleChemicalList>Antigens, Protozoan;Epitopes;Histocompatibility Antigens Class II;Ligands;Peptide Fragments;Protozoan Proteins;Receptors, Antigen, T-Cell, alpha-beta;Recombinant Fusion Proteins;Superantigens;LACK antigen, Leishmania;Interleukin-4;Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Amino Acid Substitution; Animals; Antigens, Protozoan(immunology); Disease Susceptibility; Epitopes(immunology); Female; Histocompatibility Antigens Class II(immunology); Immune Tolerance; Immunity, Cellular; Interferon-gamma(metabolism); Interleukin-4(metabolism); Leishmania major(immunology); Leishmaniasis, Cutaneous(immunology); Ligands; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Molecular Sequence Data; Peptide Fragments(chemical synthesis; immunology); Protozoan Proteins(chemistry; immunology); Receptors, Antigen, T-Cell, alpha-beta(genetics; immunology); Recombinant Fusion Proteins(immunology); Superantigens(immunology); Th2 Cells(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>189</Volume>
                <Issue>7</Issue>
                <Title>The Journal of experimental medicine</Title>
                <Issn>0022-1007</Issn>
                <MedlineTa>J Exp Med</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ICFSPSLEHPIVVSGSWD</LinearSequence>
                        <StartingPosition>156</StartingPosition>
                        <EndingPosition>173</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q25306.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>5664</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>25498</EpitopeId>
                <ReferenceStartingPosition>156</ReferenceStartingPosition>
                <ReferenceEndingPosition>173</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>1372469</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000011</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the TCR transgenic mice and the backcrossing onto BALB/c TCR-Cα&lt;sup&gt;0&lt;/sup&gt; was previously described (J. Immunol. 160:884).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>ABLE</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>183</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ICFSPSLEHPIVVSGSWD</LinearSequence>
                                        <StartingPosition>156</StartingPosition>
                                        <EndingPosition>173</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q25306.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5664</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Proliferative capacity as well as IL-4 and IFN-γ production is seen after incubation with peptide in transgenic T cells expressing an epitope-specific TCR, but is not seen after stimulation with H164N or H164K peptides, indicating that the H164 is a critical TCR contact residue. Furthermore, the altered peptides are antagonists of the WT peptide-mediated activation of these T cells. Also, the activation of those cells after in vitro inoculation with the LACK protein is not seen if the mice are immunized with proteins with a H164 alteration. This correlated with the lower IL-4 production in WT mice after inoculation with variant proteins compared to those immunized with WT protein. The antagonistic activity of the altered peptides is able to modulate the immune response, enabling the susceptible strain BALB/c to limit the infection.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>1372473</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000011</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the TCR transgenic mice and the backcrossing onto BALB/c TCR-Cα&lt;sup&gt;0&lt;/sup&gt; was previously described (J. Immunol. 160:884).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>ABLE</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>183</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ICFSPSLEHPIVVSGSWD</LinearSequence>
                                        <StartingPosition>156</StartingPosition>
                                        <EndingPosition>173</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q25306.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5664</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>78</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Proliferative capacity as well as IL-4 and IFN-γ production is seen after incubation with peptide in transgenic T cells expressing an epitope-specific TCR, but is not seen after stimulation with H164N or H164K peptides, indicating that the H164 is a critical TCR contact residue. Furthermore, the altered peptides are antagonists of the WT peptide-mediated activation of these T cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>1372470</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000011</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the TCR transgenic mice and the backcrossing onto BALB/c TCR-Cα&lt;sup&gt;0&lt;/sup&gt; was previously described (J. Immunol. 160:884).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AssayedTcrMolecule>
                            <AssayedTcrMoleculeName>ABLE</AssayedTcrMoleculeName>
                        </AssayedTcrMolecule>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>183</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ICFSPSLEHPIVVSGSWD</LinearSequence>
                                        <StartingPosition>156</StartingPosition>
                                        <EndingPosition>173</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q25306.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5664</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Proliferative capacity as well as IL-4 and IFN-γ production is seen after incubation with peptide in transgenic T cells expressing an epitope-specific TCR, but is not seen after stimulation with H164N or H164K peptides, indicating that the H164 is a critical TCR contact residue. Furthermore, the altered peptides are antagonists of the WT peptide-mediated activation of these T cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table 1</LocationOfData>
                        <MhcBindingId>205621</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>63.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>183</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>ICFSPSLEKPIVVSGSWD</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>25499</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database. This peptide is studied as an analog of the naturally occuring peptide ICFSPSLEHPIVVSGSWD.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table 1</LocationOfData>
                        <MhcBindingId>205622</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>68.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>183</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>ICFSPSLENPIVVSGSWD</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>25500</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database. This peptide is studied as an analog of the naturally occuring peptide ICFSPSLEHPIVVSGSWD.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table 1</LocationOfData>
                        <MhcBindingId>205623</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>100.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>183</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ISQAVHAAHAEINE</LinearSequence>
                        <StartingPosition>324</StartingPosition>
                        <EndingPosition>337</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAA48998.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9031</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>28673</EpitopeId>
                <ReferenceStartingPosition>323</ReferenceStartingPosition>
                <ReferenceEndingPosition>336</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table 1</LocationOfData>
                        <MhcBindingId>205624</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>150.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>183</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

